Plain-English translation of NCT07055399 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a combination of two immunotherapy medications called iparomlimab and tuvonralimab, given together with chemotherapy drugs, as a pre-surgery treatment for locally advanced cervical cancer. The goal is to shrink the cancer before surgery and help your body's immune system fight the disease more effectively. You would receive this treatment in cycles over several weeks before having surgery to remove the cancer.
Locally advanced cervical cancer is difficult to treat, and current standard treatments don't work well for all patients. Researchers believe that combining this new immunotherapy approach with chemotherapy might be more effective at shrinking tumors before surgery and improving outcomes for people with this diagnosis.
You likely qualify if…
You likely don't qualify if…
You would visit the hospital or clinic to receive intravenous infusions of the medication and chemotherapy drugs. Your first cycle includes all the medications together, followed by two more cycles of just the immunotherapy medications, with each cycle spaced three weeks apart. After completing three cycles of treatment, you would have imaging tests to see how well the cancer has responded. If the cancer shrinks, you would then have surgery to remove it. Throughout the trial, you would have regular blood tests and medical check-ups to monitor your health and how your body is responding to treatment.
AI-generated summary from trial data · Aug 14, 2026 · Not medical advice
China